Correlation Engine 2.0
Clear Search sequence regions


  • ESPs (2)
  • heparin (8)
  • humans (1)
  • nurses (1)
  • nurses practices (1)
  • patients (1)
  • pharmacy (2)
  • syringes (1)
  • university (3)
  • Sizes of these terms reflect their relevance to your search.

    In a context of heparin shortage, we studied the wasted quantities in three intensive care units (ICU) of a university hospital where two electric syringe pump (ESP) heparin protocols coexist (20,000UI/48mL used in the cardiology ICU and 25,000UI/50mL use in the medical and surgical ICUs). We performed a prospective observational study of patients treated with heparin ESP. We collected the information recorded in the prescription software connected to the ESP (dosage, start time, infusion rate, interruption times, date and time of end of treatment). We observed the ESPs, noted the time of start written on the label and the quantity remaining, and questioned nurses about the constraints that lead for changing the ESPs. Between 23/03/23 and 19/05/23, 164 vials of 25,000UI/5mL were used. The wasted quantity was equivalent 42 vials: 18 vials (43%) of treatment stopped, nurses practices such as changing the ESP in advance 6 vials (14%), application of the rule "discard the ESP 24hours after preparation" 9 vials (21.5%) and 9 vials (21.5%) corresponding to the 45mL discarded for the 45 ESP prepared in the cardiology ICU. More than a quarter of the heparin purchased is wasted. The results should lead to policy decisions concerning the medications supply chain, i.e. abandoning the 20,000UI/48mL protocol, supply of ready to use heparin syringes by industry or by the pharmacy. It is essential that these data be fed back to nurses' teams, in order to gather their suggestions before considering any changes of their practices. Copyright © 2024 Académie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.

    Citation

    Maria Paola Franchina, Bruno Charpiat. Unfractionned heparin wastage at a French university hospital]. Annales pharmaceutiques francaises. 2024 May;82(3):575-583

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38340805

    View Full Text